镰状细胞病患者移植后病毒特异性T细胞治疗的结果
单中心报告13例镰状细胞病(SCD)患者接受造血干细胞移植(HSCT)后使用病毒特异性T细胞(VST)预防或治疗病毒感染的结果。活动性病毒血症患者80%(4/5)达到至少1种目标病毒缓解,预防性输注后6/7(85.7%)保持无病毒,无即刻输注相关毒性,严重新发急性GVHD仅2例(15.4%)。
要点
- 13例SCD患者HSCT后接受15份VST产品,用于治疗或预防多种病毒。
- 活动性病毒血症患者80%(4/5)达到至少1种目标病毒缓解。
- 预防性输注后6/7(85.7%)保持无病毒,严重新发急性GVHD仅2例(15.4%)。
核心结论
- 鉴于良好的安全性、高临床缓解率及持续缓解,HSCT后常规使用VST作为预防或治疗可能改善SCD患者移植的整体安全性。
研究设计与样本
- 单中心报告13例因SCD接受HLA相合(n=9)或不相合(n=4)供者HSCT后接受VST治疗或预防病毒感染的患者。
主要发现
- 13例患者共接受15份VST产品,用于治疗或预防巨细胞病毒、EB病毒、腺病毒、BK病毒、人类疱疹病毒6型±人副流感病毒3型。
- 46.2%(n=6)的患者接受VST作为病毒感染的治疗,其中活动性病毒血症患者80%(n=4/5)达到至少1种目标病毒缓解。
- 7例(53.8%)接受预防性VST,其中6/7(85.7%)输注后保持无病毒。
- 无即刻输注相关毒性,严重新发急性GVHD仅2例(15.4%)。
临床怎么用
- 作者认为,在标准抗病毒治疗基础上,HSCT后常规使用VST作为预防或治疗可能改善SCD患者移植的整体安全性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic stem cell transplantation (HSCT) is being increasingly used as a curative approach for sickle cell disease (SCD). With the risk of graft-versus-host disease (GVHD), especially in the human leukocyte antigen-mismatched donors, intense immunosuppression is required leading to an increased risk of viral infection. Post-HSCT, adoptive transfer of virus-specific T-cell (VST) therapies have not been well-studied in patients with SCD. Here, we report the outcomes of patients with SCD at a single-center who received VSTs after transplant to prevent or treat viral infections. Thirteen patients who received HSCT from human leukocyte antigen-matched (n = 9) or -mismatched (n = 4) donors for SCD were treated with a total of 15 VST products for the treatment or prophylaxis of multiple viruses (cytomegalovirus, Epstein-Barr virus, adenovirus, BK virus, human herpes virus 6 +/- human parainfluenza virus 3). Of the patients evaluated, 46.2% (n = 6)) received VSTs as treatment for viral infection. Eighty percent of patients with active viremia (n = 4/5) achieved remission of at least 1 target virus. Seven additional patients (53.8%) received VSTs prophylactically and 6 of 7 (85.7%) remained virus-free after infusion. No immediate infusion-related toxicities occurred, and severe de novo acute GVHD occurred in only 2 (15.4%) patients. Given the good safety profile, high-rate of clinical responses and sustained remissions when administered with standard antiviral treatments, the routine use of VSTs after HSCT as prophylaxis or treatment may improve the overall safety of transplant for patients with SCD.
引用
- Kinoshita H, Mandava M, Jensen-Wachspress M, et al. Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease. Blood Adv. 2023. PMID: 36516084. doi:10.1182/bloodadvances.2022008219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。